<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; VBP</title>
	<atom:link href="http://www.tapanray.in/tag/vbp/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Policy Execution Gap Limits Access To Affordable Medicines?</title>
		<link>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-policy-execution-gap-limits-access-to-affordable-medicines</link>
		<comments>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/#comments</comments>
		<pubDate>Mon, 15 Oct 2018 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2001]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[declaration]]></category>
		<category><![CDATA[Doha]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[execution]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[payers]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9215</guid>
		<description><![CDATA[“The cost of new drugs is putting increasing pressure on people in both rich and poor countries”- was eloquently expressed in an article, titled “Why do new medicines cost so much, and what can we do about it?”. This was &#8230; <a href="http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-policy-execution-gap-limits-access-to-affordable-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making Drug Pricing Transparent May Work Better Than Price Control</title>
		<link>http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-drug-pricing-transparent-may-work-better-than-price-control</link>
		<comments>http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/#comments</comments>
		<pubDate>Mon, 23 Jul 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Michelin]]></category>
		<category><![CDATA[Monsanto]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparent]]></category>
		<category><![CDATA[value based pricing]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9060</guid>
		<description><![CDATA[“Now, one-fourth of the Indian pharma market to be under price control.” This possibility was reported by some national dailies, on July 03, 2018. The new methodology of drug price control could be anything – ranging from earlier ‘cost-based’ model to the &#8230; <a href="http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-drug-pricing-transparent-may-work-better-than-price-control/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Paying For The Best Health Outcomes At The Lowest Possible Cost</title>
		<link>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=paying-for-the-best-health-outcomes-at-the-lowest-possible-cost</link>
		<comments>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/#comments</comments>
		<pubDate>Mon, 08 Dec 2014 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[best]]></category>
		<category><![CDATA[Burrill]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[Gallup]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Levitra (vardenafil)]]></category>
		<category><![CDATA[Marijn]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Michael Porter]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[OBP]]></category>
		<category><![CDATA[Outcomes. Lowest]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[QALY]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas Lee]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>
		<category><![CDATA[Velcade (bortezomib)]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6244</guid>
		<description><![CDATA[“Bayer CEO Dr. Marijn Dekkers is happy to have fair Outcomes-Based Pricing”, reported ‘PharmaTimes’ on December 3, 2014. Dr. Dekkers was quoted saying, “It is okay to be tested on that in the process of price-setting, that is fine, we should &#8230; <a href="http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/paying-for-the-best-health-outcomes-at-the-lowest-possible-cost/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The concept of ‘Value Based Pricing (VBP)’ gaining ground to reduce cost of healthcare and improve access…but India is quite different</title>
		<link>http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different</link>
		<comments>http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/#comments</comments>
		<pubDate>Mon, 13 Dec 2010 01:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[Concept]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[different]]></category>
		<category><![CDATA[gaining]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[improve]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[patent patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[quite]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[reference]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[VBP]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=335</guid>
		<description><![CDATA[So far as the pharmaceutical pricing and increasing access to healthcare are concerned, year 2010 perhaps will be remembered as one of the very significant years, at least, in the recent times. In this year with new healthcare reform, President &#8230; <a href="http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-concept-of-value-based-pricing-vbp-gaining-ground-to-reduce-cost-of-healthcare-and-improve-accessbut-india-is-quite-different/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
